U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 10-QSB   x
        QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2005  o
        TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  Commission File No. 000-50214   BIOTEX HOLDINGS, INC. (Exact name of small business issuer as specified in its charter)     Florida
        65-0968839(State or other jurisdiction of incorporation or organization)
        (I.R.S. Employer Identification No.)  1400 Cypress Creek Road Fort Lauderdale, Florida 33309 (Address of Principal Executive Offices) 954-776-6600 (Issuers telephone number)  Capital Ventures Group I, Inc. 22154 Martella Avenue, Boca Raton, Florida 33433 (Former name, address and fiscal year, if changed since last report) Check whether the issuer (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for
such shorter period that the issuer was required to file such reports), and
(2)has been subject to such filing requirements for the past 90 days. YesxNoo Check whether the registrant has filed all documents and reports required to be
filed by Sections 12, 13, or 15(d) of the Exchange Act subsequent to the
distribution of securities under a plan confirmed by a court. YesxNoo State the number of shares outstanding of each of the issuers classes of common equity, as of August 19, 2005: 12,837,200 shares of common stock.           BIOTEX HOLDINGS, INC. FINANCIAL STATEMENTS INDEX PART I-- FINANCIAL INFORMATION Item 1.
        Financial StatementsItem 2.
        Managements Discussion and Analysis of Financial ConditionItem 3.
        Control and Procedures PART II-- OTHER INFORMATION Item 1.
        Legal ProceedingsItem 2.
        Changes in SecuritiesItem 3.
        Defaults Upon Senior SecuritiesItem 4.
        Submission of Matters to a Vote of Security HoldersItem 5.
        Other InformationItem 6.
        Exhibits and Reports on Form 8-K SIGNATURE  Item 1.
        Financial Information BASIS OF PRESENTATION The accompanying reviewed financial statements are presented in accordance with generally accepted accounting principles for interim financial information and the instructions to Form 10-QSB and item 310 under subpart A of Regulation S-B. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting only of normal occurring accruals) considered necessary in order to make the financial statements not misleading, have been included. Operating results for the six months ended June 30, 2005 are not necessarily indicative of results that may be expected for the year ending December 31, 2005. The financial statements are presented on the accrual basis.          BIOTEX CORPORATION  CONDENSED FINANCIAL STATEMENTS  June 30, 2005   TABLE OF CONTENTS       PageCondensed Balance Sheet
        2Condensed Statements of Operations
        3Condensed Statements of Cash Flows
        4Notes to Condensed Financial Statements
        5-7                 BIOTEX CORPORATIONCONDENSED BALANCE SHEETSJune 30,2005(Unaudited)ASSETSCurrent Assets:Cash and cash equivalents
        
        
        $
        324,539Prepaid expenses and other current assets
        
        
        
        9,931Total Current Assets
        
        
        
        334,470Furniture and equipment, net
        
        
        
        
        7,220Research and development equipment, net
        
        
        
        76,964Note receivable - related party
        
        
        
        3,520Intellectual property
        
        
        
        
        18,750,000Total Assets
        
        
        
        
        $
        19,172,174LIABILITIES AND SHAREHOLDERS EQUITYCurrent Liabilities:Accounts payable and accrued expenses
        
        
        $
        78,765Note payable - related party
        
        
        
        95,000Total Current Liabilities
        
        
        
        173,765Shareholders Equity:Common stock, $0.0001 par value, 20,000,000shares authorized, 12,837,200 shares issued and outstanding
        
        1,284Additional paid-in capital
        
        
        
        19,373,716Accumulated deficit
        
        
        
        
        (376,591)Total Shareholders Equity
        
        
        
        18,998,409Total Liabilities and Shareholders Equity
        
        
        $
        $     19,172,174 The accompanying notes are an integral part of these financial statements. 2         BIOTEX CORPORATIONCONDENSED STATEMENTS OF OPERATIONSSix Months Ended June 30,2005
        
        
        2004(Unaudited)
        
        
        (Unaudited)NET SALES
        
        
        
        
        $
        -
        
        $
        -Cost of goods sold
        
        
        
        
        
        479
        
        
        -GROSS PROFIT
        
        
        
        
        
        (479)
        
        
        -Operating ExpensesGeneral and administrative expenses
        
        
        59,458
        
        
        -Depreciation and amortization
        
        
        
        4,550
        
        
        -Research and development
        
        
        
        20,000
        
        
        -Management and consulting fees
        
        
        
        178,120Professional fees
        
        
        
        
        26,921
        
        
        -Total operating expenses
        
        
        
        
        289,049
        
        
        -Other Income/ExpenseOther income
        
        
        
        
        303Other expense
        
        
        
        
        40LOSS BEFORE PROVISION FOR INCOME TAXES
        
        
        (289,265)
        
        
        -Provision for income taxes
        
        
        
        
        -
        
        
        -Net Loss
        
        
        
        
        
        $
        (289,265)
        
        $
        -Net loss per share - basic and diluted
        
        
        $
        (0.023)
        
        $
        -Weighted average number of commonshares outstanding - basic and diluted
        
        
        12,840,800
        
        
        -  The accompanying notes are an integral part of these financial statements. 3          BIOTEX CORPORATIONSTATEMENTS OF CASH FLOWSSix Months Ended June 30,2005
        
        
        2004(Unaudited)
        
        
        (Unaudited)Cash Flows From Operating Activities:Net Loss
        
        
        $
        (289,265)
        
        $
        -Adjustments to reconcile net income to netcash provided by operating activities:Depreciation and amortization
        
        4,550
        
        
        -Changes in current assets and liabilities:Prepaid expenses
        
        
        (4,931)
        
        
        -Furniture and fixtures
        
        
        (9,895)
        
        
        -Research and development, equipment
        
        (78,839)
        
        
        -Note receivable - related party
        
        (3,520)
        
        
        -Accounts payable and accrued expenses
        
        78,765
        
        
        -Net Cash Provided by (Used in) Operating Activities
        
        (303,135)
        
        
        -Cash Flows from Investing Activities:-
        
        
        -Net Cash Used in Investing Activities
        
        
        -
        
        
        -Cash Flows from Financing Activities:Proceeds from related party loans
        
        -
        
        
        2,000Repayment of related party loans
        
        (5,000)
        
        
        -Issuance of common stock
        
        
        623,000
        
        
        (2,000)Net cash provided by Financing Activities
        
        
        618,000
        
        
        -Net Decrease in Cash and Cash Equivalents
        
        314,865
        
        
        -Cash and Cash Equivalents - Beginning of Period
        $
        9,674
        
        $
        -Cash and Cash Equivalents - End of Period
        $
        324,539
        
        $
        -Supplemental disclosure of cash flow information:Noncash Investing and Financing ActivitiesIssuance of common stock for intellectual property
        $
        18,750,000
        
        $
        - The accompanying notes are an integral part of these financial statements. 4        BIOTEX CORPORATION  NOTES TO CONDENSED FINANCIAL STATEMENTS  June 30, 2005   NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  Organization  BioTex  Corporation (f/k/a YB Holdings,  Inc.) (the "Company")  established
in 2003 to  develop  and  employ  technologies  from  around  the  world to
process biomass (plant derived) waste,  extract the usable  fractions,  and
then  utilize  or sell those  extractions  for  varied  applications  or in
further processes.  The financial statements are presented on the basis that the Company is a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business over a reasonable length of time. The Company has incurred operating losses since its inception. This condition raises substantial doubt as to the Companys ability to continue as a going concern.  NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  Interim Financial Statements  The accompanying interim unaudited financial information has been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations, although management believes that the disclosures are adequate to make the information presented not misleading. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the financial position of the Company as of June 30, 2005 and the related operating results and cash flows for the interim period presented have been made. The results of operations of such interim period are not necessarily indicative of the results of the full year.           BIOTEX CORPORATION  NOTES TO CONDENSED FINANCIAL STATEMENTS  June 30, 2005   Use of Estimates  Use of estimates and assumptions by management is required in the preparation of financial statements in conformity with generally accepted accounting principles. Actual results could differ from those estimates and assumptions.  Earnings Per Share  Basic earnings per share (EPS) is computed by dividing earnings available to common shareholders by the weighted-average number of common shares outstanding for the period as required by the Financial Accounting Standards Board (FASB) under Statement of Financial Accounting Standards (SFAS) No. 128, Earnings per Shares. Diluted EPS reflects the potential dilution of securities that could share in the earnings.  Reclassification  Certain prior period amounts have been reclassified to conform to current presentations.  NOTE 3 - INCOME TAXES  At June 30, 2005, there are no items that give rise to deferred income taxes.  NOTE 4  INTELLECTUAL PROPERTY  During May 2005,  the Company  entered into an agreement with an individual
who is the sole inventor of and holds all the rights,  title,  and interest
in a pending patent for citrus separation  technology,  whereby the Company
has been  assigned  the pending  patent and the right to make and have made
and to use, offer to sell,  sell,  license,  rent, and distribute  products
embodying  the  citrus  separation  technology  and  improvements  to  such
technology   throughout   the   entire   world.   In   exchange   for   the
aforementioned  pending patent,  the Company has agreed to pay the issuance
of  500,000  shares of YB common  stock and an option for the  purchase  of
300,000  additional  shares of YB common stock,  exercisable  at a price of
$5.00 per share.  The Company also agreed to share a certain  percentage of
profits derived from sales.        BIOTEX CORPORATION  NOTES TO CONDENSED FINANCIAL STATEMENTS  June 30, 2005   During May 2005, the Company entered into an agreement with Mastercraft Corporation Limited, a private company organized and in good standing pursuant to the laws of the United Kingdom whereby the Company has been assigned all the machinery, processes, hardware, software, systems, subsystems, and components embodied in or relating to molecular separation technology (MST) and any future model or generation. In exchange for the aforementioned assignment, the Company has agreed to pay the following:  
        The sum of $1,000,000, which will be held in escrow until after the technology transfer has been completed,
        The in-kind sum of $16,250,000, payable by issuance of 6,500,000 shares of common stock in the Company or its successor, valued at $2.50 per share. Such shares will be held in escrow until after the technology transfer has been completed, and
        The performance-based sum of $8,000,000, payable over an unspecified number of periods. Payments will be 15% of the net profits derived from the licensing, leasing, rental, and use of products embodying the molecular separation technology in each calendar quarter, and are payable 30 days after the end of each calendar quarter.  NOTE 5  SUBSEQUENT EVENTS  During  August  2005,  the Company  formed a  majority-owned  venture,  BTX
Citrus Belize,  Ltd.  (hereinafter  known as "BTXC"),  with Citrus Products
Of Belize Ltd.  ("CPBL"),  comprised of the Company's  capital  funding and
citrus peel processing  equipment.  CPBL is providing the land, free citrus
peel for 10 years  and is  placing  $700,000  in an  escrow  account  for a
period of no  longer  than four  months.  As a result of this  transaction,
BioTex Corp.  ("BIOTEX") will have a 65% ownership interest.  The remaining
35% shall be owned by Citrus Products Of Belize Ltd. ("CPBL").              Item 2.
        Managements Discussion and Analysis or Plan of Operation General  The Company was incorporated on December 17, 1999, under the laws of the State
of Florida to engage in any lawful corporate undertaking, including, but not
limited to, selected mergers and acquisitions. We had been in the developmental
stage since inception and had no operations to date other than issuing shares to
our original shareholders. The business plan of the Company was to locate and
negotiate with a business entity for the combination of that target company with
us with the combination normally in the form of a merger, stock-for-stock
exchange or stock-for-assets exchange.  The Company has successfully located and negotiated an agreement to acquire all of the shares of YB Holdings, Inc. which is a Florida corporation which was established in 2003 to develop and employ technologies from around the world to process biomass (plant derived) waste, extract the usable fractions, and then utilize or sell those extractions in further downstream processes. On June 9, 2005, the Company completed a Stock Purchase Agreement and Share Exchange with YB Holdings, Inc. pursuant to which the Company purchased all of the outstanding shares of YB Holdings for a total of 12,272,200 shares of the Companys common stock. Pursuant to the Agreement, YB Holdings became a wholly owned subsidiary of the Company and the Company changed its named to BioTex Holdings, Inc.  In May 2005, YB Holdings  entered into an agreement  with an individual who
is the sole  inventor of and holds all the rights,  title,  and interest in
a pending  patent for citrus  separation  technology,  whereby  the Company
has been  assigned  the pending  patent and the right to make and have made
and to use, offer to sell,  sell,  license,  rent, and distribute  products
embodying  the  citrus  separation  technology  and  improvements  to  such
technology   throughout   the   entire   world.   In   exchange   for   the
aforementioned  pending  patent,  YB Holdings has agreed to the issuance of
500,000  shares  of YB  common  stock and an  option  for the  purchase  of
300,000  additional  shares of YB common stock,  exercisable  at a price of
$5.00 per share.  YB Holdings also agreed to share a certain  percentage of
profits derived from sales.  During May 2005, YB Holdings entered into an agreement with Mastercraft Corporation Limited, a private company organized and in good standing pursuant to the laws of the United Kingdom whereby YB Holdings has been assigned all the machinery, processes, hardware, software, systems, subsystems, and components embodied in or relating to molecular separation technology (MST) and any future model or generation. In exchange for the aforementioned assignment, the Company has agreed to pay the following:  
        The sum of $1,000,000 (US), which will be held in escrow until after the technology transfer has been completed,
        The in-kind sum of $16,250,000 (US), payable by issuance of 6,500,000 shares of common stock in YB Holdings or its successor, valued at $2.50 (US) per share. Such shares will be held in escrow until after the technology transfer has been completed, and The performance-based sum of $8,000,000 (US), payable over an unspecified number of periods. Payments will be 15% of the net profits derived from the licensing, leasing, rental, and use of products embodying the molecular separation technology in each calendar quarter, and are payable 30 days after the end of each calendar quarter.  Capital Resources and Liquidity.  As  of  June  30,  2005,   we  had  $324,539  in  cash.   Our  general  and
administrative  expenses are expected to average  $45,000 per month for the
next 12 months based upon our projected  operating budget.  These projected
expenses do not include  any costs that may be  incurred  for the  building
of plants pursuant to the Belize or any other potential  agreement.  We can
currently  satisfy  7 months of  operations  without  receiving  additional
funds from our President or additional  investors.  During May 2005,  prior
to  the  merger,   YB  Holdings   completed   the  private   placement   of
approximately  $600,000  through private sales of its common stock at $1.00
per share.         Our operating activities used cash of $287,157 in the six months ending June 30, 2005. As of June 30, 2005, we had total current assets of $417,496 including cash of $324,539 As of June 30, 2005 our total current liabilities amounted to $177,952. Through the date of the acquisition, all of the costs and expenses incurred by the Company were paid for by its principal shareholder.  Critical Accounting Policies  BioTexs financial statements and related public financial information are based on the application of accounting principles generally accepted in the United States (GAAP). GAAP requires the use of estimates; assumptions, judgments and subjective interpretations of accounting principles that have an impact on the assets, liabilities, revenue and expense amounts reported. These estimates can also affect supplemental information contained in our external disclosures including information regarding contingencies, risk and financial condition. We believe our use if estimates and underlying accounting assumptions adhere to GAAP and are consistently and conservatively applied. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions
or conditions. We continue to monitor significant estimates made during the preparation of our financial statements.  Our significant accounting policies are summarized in Note 1 of our financial statements. While all these significant accounting policies impact its financial condition and results of operations, BioTexs views certain of these policies as critical. Policies determined to be critical are those policies that have the most significant impact on BioTexs consolidated financial statements and require management to use a greater degree of judgment and estimates. Actual results may differ from those estimates. Our management believes that given current facts and circumstances, it is unlikely that applying any other reasonable judgments or estimate methodologies would cause effect on our consolidated results of operations, financial position or liquidity for the periods presented in this report.  Item 3.
        Controls and Procedures  (a)
        Evaluation of disclosure controls and procedures. Our Chief Executive Officer and Chief Financial Officer (collectively the Certifying Officers) maintain a system of disclosure controls and procedures that is designed to provide reasonable assurance that information, which is required to be disclosed, is accumulated and communicated to management timely. Under the supervision and with the participation of management, the Certifying Officers evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule [13a-14(c)/15d-14(c)] under the Exchange Act) within 90 days prior to the filing date of this report. Based upon that evaluation, the Certifying Officers concluded that our disclosure controls and procedures are effective in timely alerting them to material information relative to our company required to be disclosed in our periodicfilings with the SEC. (b)
        Changes in internal controls. Our Certifying Officer has indicated that there were no significant changes in our internal controls or other factors that could significantly affect such controls subsequent to the date of his evaluation, and there were no such control actions with regard to significant deficiencies and material weaknesses.           PART II - OTHER INFORMATION Item 1.
        Legal Proceedings.  The Company is currently not a party to any pending legal proceedings and no such action by, or to the best of its knowledge, against the Company has been threatened.  Item 2.
        Changes in Securities.  On June 9, 2005, pursuant to the Stock Purchase Agreement and Share Exchange, the Company issued a total of a total of 12,272,200 shares of the Companys common stock to the shareholders of YB Holdings in exchange for all of the outstanding shares of YB Holdings. These shares were issued in reliance on an exemption from registration under Section 4(2) of the Securities Act of 1933. These shares of our common stock qualified for exemption under Section 4(2) of the Securities Act of 1933 since the issuance of shares by us did not involve a public offering. The offering was not a public offering as defined in Section 4(2) due to the insubstantial number of persons involved in the deal, the size of the offering, and the manner of the offering. We did not undertake an offering in which we sold a high number of shares to a high number of investors. In addition, YB Holdings had the necessary
investment intent as required by Section 4(2) since the YB Holdings shareholders agreed to and received share certificates bearing a legend stating that such shares are restricted pursuant to Rule 144 of the 1933 Securities Act. This restriction ensures that these shares would not be immediately redistributed into the market, and therefore not be part of a public offering.  Item 3.
        Defaults Upon Senior Securities.  None  Item 4.
        Submission of Matters to a Vote of Security Holders.  No matter was submitted during the quarter ending June 30, 2005,covered by this report to a vote of the Companys shareholders, through the solicitation of proxies or otherwise.  Item 5.
        Other Information.  None  Item 6.
        Exhibits and Reports of Form 8-K.  (a)
        Exhibits  31.1 Certification pursuant to Section 302 of Sarbanes Oxley Act of 200232.1 Certification pursuant to Section 906 of Sarbanes Oxley Act of 2002  (b)
        Reports of Form 8-K  On June 15, 2005, the Company filed an 8K based on a change in control of the Company.         SIGNATURES  In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, there unto duly authorized.  BIOTEX HOLDINGS, INC.Registrant  Date: August 22, 2005
        By: /s/ Scott SilvermanScott SilvermanPresident